ABBOTT PARK, Ill.,
April 18, 2013
/PRNewswire/ -- Abbott (NYSE: ABT) today announced that the TECNIS
Toric 1-Piece intraocular lens (IOL) has received U.S. Food and Drug Administration (FDA) approval and is launching in
the United States
for the treatment of cataract patients with pre-existing corneal astigmatism.
Corneal astigmatism is a condition where the curvature of the cornea is uneven, preventing light rays from focusing clearly on the retina, resulting in blurred vision. Intraocular lenses are implanted in a patient's eye after the removal of the natural lens that has become clouded by a cataract. Unlike conventional IOLs, the TECNIS Toric 1-Piece IOL can correct a patient's loss of focus due to pre-existing corneal astigmatism of one diopter (a unit of measurement of the refractive power of a lens) or greater.
The average age for the cataract surgery patient in
the United States
is approximately 68 years with more than 3.5 million procedures performed annually. As the U.S. population continues to age, the number of cataract surgeries is expected to grow nearly 3 percent each year, increasing patient demand for improved, precise visual outcomes and independence from glasses.
"The TECNIS Toric 1-Piece IOL represents the latest advancement in cataract technology and expands Abbott's portfolio of the TECNIS family of IOLs," said
, senior vice president, Medical Optics, Abbott. "The TECNIS Toric 1-Piece IOL allows surgeons to offer an additional lens option that provides proven visual outcomes to increase patient satisfaction."
Along with delivering precise visual outcomes for patients, rotational stability is an important attribute of a toric IOL. The TECNIS Toric 1-piece IOL remains very stable once inserted into the eye, and meets the new standard for toric IOL rotational stability, as approved by the American National Standards Institute (ANSI).